Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer.

ABSTRACT:

Importance

A circulating tumor DNA (ctDNA) assay (Signatera; Natera) has been marketed for use in the surveillance of resected colorectal cancer despite limited data supporting such practice.

Objective

To compare a ctDNA assay with standard radiographic imaging and measurement of carcinoembryonic antigen (CEA) levels, per National Comprehensive Cancer Network guidelines, in the surveillance of resected colorectal cancer.

Design, setting, and participants

This retrospective, single-center cohort study evaluated surveillance strategies of ctDNA, imaging, and measurement of CEA levels in patients with resected colorectal cancer from September 1, 2019, to November 30, 2021.

Main outcomes and measures

The sensitivity and specificity of ctDNA, imaging, measurement of

SUBMITTER: Fakih M 

PROVIDER: S-EPMC8905389 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature